Were these results already known?

Yes. The key top-line and bottom-line figures were disclosed in a preliminary filing earlier. This is the audited version with the audit opinion and an internal auditor appointment.

What does an unmodified audit opinion mean?

It means the statutory auditors found the financial statements fairly presented and in compliance with accounting standards. No red flags were raised.

How material is ₹47.62 cr revenue for a ₹31 cr market cap company?

Revenue is 1.5x the market cap, which is typical for low-margin pharma. But net profit of ₹0.60 cr is just 1.9% of revenue, suggesting very thin margins.

Earnings · Pharmaceuticals · Micro cap

Panjon's FY26 results get clean audit, but no surprises

Audited numbers confirm 56% revenue jump to ₹47.62 cr, but net profit remains thin at ₹0.60 cr. All key figures were already disclosed.

— 1 earlier story on Panjon Ltd. →

PANJON By Tipsheet Editorial 20 Jun 2026 · 2:37 PM IST Verify on BSE · NSE

Mkt cap₹30.45 cr

P/E50.83×

ROE2.47%

Debt / eq.0.16

₹47.62 cr FY26 revenue, up 56% YoY

What's new

Statutory auditors issued an unmodified opinion on FY26 financials.
Board appointed M/s B. Jakhetiya & Co as internal auditor for FY27.
No material deviation from preliminary numbers disclosed earlier.

Why this matters

For a ₹31 cr nano-cap, a 56% revenue jump is notable. But net profit of just ₹0.60 cr means margins remain razor-thin - trailing ROE of 2.5% says it all. The clean audit is reassuring, but it is procedural, not value-creating.

What we're watching

Q1 FY27 numbers - after Q4 contraction, can growth sustain?
Margin trajectory given the 2.5% ROE base.
Any operational or regulatory update for such a small pharma player.

The full read

Panjon's FY26 audited numbers confirm what the market already knew: revenue jumped 56% to ₹47.62 cr, but net profit crept just 11% higher to ₹0.60 cr. For a ₹31 cr nano-cap, the top-line growth is eye-catching, but trailing ROE of 2.5% tells the real story. This is a high-volume, low-margin business. The unmodified audit opinion and routine internal auditor appointment add no fresh news. With Q4 already showing contraction per our prior coverage, the open question is whether the growth trend can continue into FY27. Until then, this filing is a procedural checkbox, nothing more.

Questions answered

Were these results already known?: Yes. The key top-line and bottom-line figures were disclosed in a preliminary filing earlier. This is the audited version with the audit opinion and an internal auditor appointment.
What does an unmodified audit opinion mean?: It means the statutory auditors found the financial statements fairly presented and in compliance with accounting standards. No red flags were raised.
How material is ₹47.62 cr revenue for a ₹31 cr market cap company?: Revenue is 1.5x the market cap, which is typical for low-margin pharma. But net profit of ₹0.60 cr is just 1.9% of revenue, suggesting very thin margins.

Mentioned: M/s B. Jakhetiya & Co · FY26 audited results · ₹47.62 cr revenue

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Panjon Ltd.

Pharmaceuticals

₹30 cr

P/E 50.81×

Latest quarter · Mar 2026

Sales₹12 cr

Net profit₹0 cr

Op. margin+2.0%

EPS₹0.04

Strength & growth

Debt / equity0.16×

Current ratio3.69×

Sales CAGR+15.1%

Story so far

All notes on PANJON →

20 Jun 2026 · 2:37 PM IST Panjon's FY26 results get clean audit, but no surprises
38d ago Panjon's full-year revenue surges 56%, but the last quarter contracts